Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 179

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens

Open access
Abhishek Maiti, Caitlin R. Rausch, Jorge E. Cortes, Naveen Pemmaraju, Naval G. Daver, Farhad Ravandi, Guillermo Garcia-Manero, Gautam Borthakur, Kiran Naqvi, Maro Ohanian, Nicholas J. Short, Yesid Alvarado, Tapan M. Kadia, Koichi Takahashi, Musa Yilmaz, Nitin Jain, Steven Kornblau, Guillermo Montalban Bravo, Koji Sasaki, Michael Andreeff, Prithiviraj Bose, Alessandra Ferrajoli, Ghayas C. Issa, Elias J. Jabbour, Lucia Masarova, Philip A. Thompson, Sa Wang, Sergej Konoplev, Sherry A. Pierce, Jing Ning, Wei Qiao, John S. Welch, Hagop M. Kantarjian, Courtney D. DiNardo, Marina Y. Konopleva · 2020 · Haematologica

Abstract

Outcomes of relapsed or refractory acute myeloid leukemia after front-line hypomethylating agent and venetoclax regimensAcute myeloid leukemia (AML) is the most common acute leukemia in adults.][6] Consequently, VEN+HMA regimens have emerged as a reasonable new standard of care for older patients. 7However, little is known about outcomes of patients after failure of front-line venetoclax-based regimens.We found that patients failing front-line VEN+HMA have high-risk biology, dismal overall survival (OS) despite salvage therapy, and new putative mechanisms of resistance.This knowledge may help guide physicians' expectations, inform discussion with patients, and design clinical trials in patients after venetoclax failure.This was a retrospective study to determine the outcomes of patients after failure of front-line VEN+HMA therapy.Patients with newly diagnosed (ND) AML enrolled on two clinical trials of VEN and HMA at our institute, either with primary refractory disease or relapse (R/R) after initial response were included (Online Supplementary Figure S1).In one trial, patients with ND AML aged 65 years or older received venetoclax 400-1,200 mg daily with decitabine 20 mg/m 2 for 5 days or azacitidine 75 mg/m 2 for 7 days every 4 weeks (clinicaltrials.govidentifier: NCT02203773). 4The other trial enrolled patients with ND AML aged 60 years or older, and patients received venetoclax 400 mg daily or equivalent with decitabine 20 mg/m 2 for 10 days every 4 weeks until response, followed by 5-day decitabine with venetoclax cycles (clinicaltrials.govidentifier: NCT03404193). 5None of the patients included in these analyses received any third agents such as targeted therapies.Responses included complete remission (CR), CR with incomplete hematologic recovery (CRi), or morphologic leukemia-free state (MLFS) according to the European LeukemiaNet 2017 criteria. 8Primary refractory disease was defined as lack of reduction of bone marrow (BM) blasts to 5% or less by up to cycle 4 of VEN+HMA, as originally defined in these two protocols designed in 2014 and 2017.Relapse was defined as clinically significant progressive disease with increase in BM blasts to more than 5% after achievement of CR/CRi/MLFS.OS was measured from the date of establishment of primary refractory disease or relapse after VEN+HMA therapy, until death or censored at last follow-up.The data cut-off date for this report was July 8 th , 2019.To provide context for this analysis, we compared outcomes, both from initial therapy, and from time of R/R disease, with front-line IC using a historical cohort.We found 278 patients treated with IC who matched for both age and European LeukemiaNet (ELN) 2017 cytogenetic risk status with 88 out of 95 patients treated with VEN+HMA.There were no patients in our historical IC cohort who matched for both age and cytogenetic risk status of seven patients who received VEN+HMA, and hence the comparison was limited to those 88 patients.Two out of those seven unmatched patients had R/R disease after VEN+HMA.The patients in the IC cohort were diagnosed between 2000 and 2018, and received treatment with IC containing at least 1 g/m 2 /day of cytarabine

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3324/haematol.2020.252569

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 179

Metadata

Authors
Maiti, A., Rausch, C. R., Cortes, J. E., Pemmaraju, N., Daver, N. G., Ravandi, F., Garcia-Manero, G., Borthakur, G., Naqvi, K., Ohanian, M., Short, N. J., Alvarado, Y., Kadia, T. M., Takahashi, K., Yilmaz, M., Jain, N., Kornblau, S., Bravo, G. M., Sasaki, K., Andreeff, M., Bose, P., Ferrajoli, A., Issa, G. C., Jabbour, E. J., Masarova, L., Thompson, P. A., Wang, S., Konoplev, S., Pierce, S. A., Ning, J., Qiao, W., Welch, J. S., Kantarjian, H. M., DiNardo, C. D., & Konopleva, M. Y.
Venue
Haematologica
Published
2020-06-04
Volume
106
Issue
3
Pages
894-898
ISSN
  • 0390-6078 (ISSN-L)
  • 1592-8721
OpenAlex
W3033696780
Cited by
179
References
2
FWCI
12.83
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens. https://app.cochat.ai/papers/10.3324/haematol.2020.252569
The paper
Maiti, A., Rausch, C. R., Cortes, J. E., Pemmaraju, N., Daver, N. G., Ravandi, F., Garcia-Manero, G., Borthakur, G., Naqvi, K., Ohanian, M., Short, N. J., Alvarado, Y., Kadia, T. M., Takahashi, K., Yilmaz, M., Jain, N., Kornblau, S., Bravo, G. M., Sasaki, K., . . . Konopleva, M. Y. (2020). Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens. Haematologica. https://doi.org/10.3324/haematol.2020.252569

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.